Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 2
2010 3
2011 7
2012 6
2013 4
2014 5
2015 15
2016 14
2017 6
2018 13
2019 9
2020 9
2021 7
2022 18
2023 19
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Update of EULAR recommendations for the treatment of systemic sclerosis.
Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors. Kowal-Bielecka O, et al. Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9. Ann Rheum Dis. 2017. PMID: 27941129 Free article.
Trial of Intravenous Immune Globulin in Dermatomyositis.
Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis C, Schiopu E, Vencovský J, Beckmann I, Clodi E, Bugrova O, Dankó K, Ernste F, Goyal NA, Heuer M, Hudson M, Hussain YM, Karam C, Magnolo N, Nelson R, Pozur N, Prystupa L, Sárdy M, Valenzuela G, van der Kooi AJ, Vu T, Worm M, Levine T; ProDERM Trial Group. Aggarwal R, et al. N Engl J Med. 2022 Oct 6;387(14):1264-1278. doi: 10.1056/NEJMoa2117912. N Engl J Med. 2022. PMID: 36198179 Clinical Trial.
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP; focuSSced investigators. Khanna D, et al. Lancet Respir Med. 2020 Oct;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. Epub 2020 Aug 28. Lancet Respir Med. 2020. PMID: 32866440 Clinical Trial.
Treatment of relapsing polychondritis: a systematic review.
Petitdemange A, Sztejkowski C, Damian L, Martin T, Mouthon L, Amoura Z, Cutolo M, Burmester GR, Fonseca JE, Rednic S, Arnaud L. Petitdemange A, et al. Among authors: rednic s. Clin Exp Rheumatol. 2022 May;40 Suppl 134(5):81-85. doi: 10.55563/clinexprheumatol/h9gq1o. Epub 2022 Jan 28. Clin Exp Rheumatol. 2022. PMID: 35238756 Free article. Review.
Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation.
Tani C, Elefante E, Arnaud L, Barreira SC, Bulina I, Cavagna L, Costedoat-Chalumeau N, Doria A, Fonseca JE, Franceschini F, Fredi M, Iaccarino L, Limper M, Majnik J, Nagy G, Pamfil C, Rednic S, Reynolds JA, Tektonidou MG, Troldborg A, Zanframundo G, Mosca M. Tani C, et al. Among authors: rednic s. Clin Exp Rheumatol. 2022 May;40 Suppl 134(5):93-102. doi: 10.55563/clinexprheumatol/jrz47c. Epub 2022 Apr 29. Clin Exp Rheumatol. 2022. PMID: 35485422 Free article. Review.
Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
Baraliakos X, Ranza R, Östör A, Ciccia F, Coates LC, Rednic S, Walsh JA, Douglas K, Gao T, Kato K, Song IH, Ganz F, Deodhar A. Baraliakos X, et al. Among authors: rednic s. Arthritis Res Ther. 2023 Apr 10;25(1):56. doi: 10.1186/s13075-023-03027-5. Arthritis Res Ther. 2023. PMID: 37038159 Free PMC article. Clinical Trial.
Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases.
Santos EJF, Farisogullari B, Dures E, Geenen R, Machado PM; EULAR taskforce on recommendations for the management of fatigue in people with inflammatory rheumatic diseases. Santos EJF, et al. RMD Open. 2023 Aug;9(3):e003350. doi: 10.1136/rmdopen-2023-003350. RMD Open. 2023. PMID: 37604639 Free PMC article.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region.
Lescoat A, Huscher D, Schoof N, Airò P, de Vries-Bouwstra J, Riemekasten G, Hachulla E, Doria A, Rosato E, Hunzelmann N, Montecucco C, Gabrielli A, Hoffmann-Vold AM, Distler O, Ben Shimol J, Cutolo M, Allanore Y; EUSTAR collaborators. Lescoat A, et al. Rheumatology (Oxford). 2023 Jun 1;62(6):2178-2188. doi: 10.1093/rheumatology/keac576. Rheumatology (Oxford). 2023. PMID: 36222557
127 results